Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4 Open-market sale VP, Clinical Trial Operations sold 3,265 shares at $23.73 ($77,478)
  2. 4 Open-market sale President and CEO sold 8,349 shares at $23.73 ($198,122)
  3. 3 Insider Initial Statement of Ownership
  4. 3 Insider Initial Statement of Ownership
  5. 4 Grant or award Director acquired 9,000 shares (grant or award)
  6. 4 Grant or award Director acquired 1,000 shares (grant or award)
  7. 4 Grant or award Director acquired 1,000 shares (grant or award)
  8. 4 Grant or award Director acquired 9,000 shares (grant or award)
  9. 4 Grant or award President and CEO acquired 23,000 shares (grant or award)
  10. 4 Grant or award Associate VP, Research acquired 6,000 shares (grant or award)
  11. 4 Grant or award General Counsel acquired 900 shares (grant or award)
  12. 4 Grant or award Chief Financial Officer acquired 3,600 shares (grant or award)
  13. 4 Grant or award VP, Clinical Trial Operations acquired 9,000 shares (grant or award)
  14. 4 Grant or award VP, Pharmaceutical Development acquired 9,000 shares (grant or award)
  15. 4 Open-market buy Associate VP, Research bought 200 shares at $6.25 ($1,250)
  16. 4 Conversion 10% owner acquired 1,000,000 shares (conversion)
  17. 4 Conversion Director acquired 470,000 shares (conversion)
  18. 4 Conversion Director acquired 11,362 shares (conversion)
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 9 of 10 · 190 filings